Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, Inc. and Certain Officers - BLUE
05:53pm, Friday, 12'th Feb 2021
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its of
New York, New York--(Newsfile Corp. - February 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
01:39pm, Tuesday, 09'th Feb 2021
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks Wall Street Thinks Will Soar 50% or More in 2021
06:08am, Sunday, 24'th Jan 2021
These stocks have one obvious thing in common.
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
02:18pm, Tuesday, 12'th Jan 2021
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
Bluebird Bio CEO talks business spinoff after a 47% loss in 2020
09:20pm, Monday, 11'th Jan 2021
Bluebird Bio, Inc. (NASDAQ: BLUE) is a gene therapy company that focuses on treatments for severe genetic diseases and cancer. Early investors that got in near the $25 level as part of Bluebird's 20
bluebird bio to Spin Off Its Oncology Business
11:51am, Monday, 11'th Jan 2021
The biotech will then focus on its rare disease programs.
Bluebird's stock is up 5% as it details plans to separate oncology and genetic disease businesses
08:11am, Monday, 11'th Jan 2021
Shares of Bluebird Bio Inc. gained 5.1% in premarket trading on Monday after it announced plans to spin off its oncology business as a separate publicly-traded company. Bluebird will retain its geneti
bluebird bio to Separate Oncology Business into Independent Company
06:30am, Monday, 11'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly tr
bluebird bio: One Of My Top Picks For 2021
02:40pm, Wednesday, 06'th Jan 2021
bluebird had a rough 2020 but we are quickly approaching several key catalysts in 2021 that will transform the company's outlook and possibly inject some momentum into the share price. ZYNTEGLO has co
bluebird bio Inc., Undervalued Acquisition Candidate
11:08am, Wednesday, 06'th Jan 2021
I estimate the fair value for BLUE between $5-7 billion based on similar acquisitions. 2021 could be an inflection point with the anticipated approval of the company's multiple myeloma treatment.
3 Top Biotech Buyout Candidates in 2021
06:09am, Monday, 04'th Jan 2021
Big drugmakers could be attracted to these smaller players with promising pipelines.
3 FDA Dates Biotech Investors Should Circle in 2021
07:34am, Thursday, 24'th Dec 2020
These biotech stocks could sink or soar following some important approval decisions slated for the new year.
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
10:00am, Thursday, 17'th Dec 2020
Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).
ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma
11:44am, Sunday, 13'th Dec 2020
Targeting BCMA is all the rage, but who will come out on top?
